Vir Biotechnology

Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?
Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?
Motley Fool
Alnylam
Vir Biotechnology
RNAi
vaccines
COVID-19
Flag link:
GSK, Vir cleared to leap into PhIII, angling for a spot in the Covid-19 antibody race led by Lilly, Regeneron
GSK, Vir cleared to leap into PhIII, angling for a spot in the Covid-19 antibody race led by Lilly, Regeneron
Endpoints
GSK
Vir Biotechnology
COVID-19
clinical trials
Flag link:
Vir and GlaxoSmithKline begin pivotal study of Covid-19 antibody drug
Vir and GlaxoSmithKline begin pivotal study of Covid-19 antibody drug
Stat
Vir Biotechnology
GSK
clinical trials
antibodies
COVID-19
Flag link:
EASL 2020 – Assembly finds a partner as hepatitis B inches forward
EASL 2020 – Assembly finds a partner as hepatitis B inches forward
EP Vantage
EASL
RNAi
hepatitis B
Assembly Biosciences
Abrutus
JNJ
GSK
Vir Biotechnology
Flag link:
Vir enlists Covid-19 antibody rival for cancer, infectious disease discovery work
Vir enlists Covid-19 antibody rival for cancer, infectious disease discovery work
Endpoints
Vir Biotechnology
Harbor BioMed
cancer
infectious diseases
Flag link:
Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral
Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral
Fierce Biotech
Alnylam
Vir Biotechnology
COVID-19
RNAi
clinical trials
Flag link:
Vir reminds biopharma its original aim is hepatitis B
Vir reminds biopharma its original aim is hepatitis B
BioPharma Dive
Vir Biotechnology
hepatitis B
VIR-2218
clinical trials
Flag link:
Vir Bio inks $362M Covid-19 contract manufacturing deal with Samsung Biologics
Vir Bio inks $362M Covid-19 contract manufacturing deal with Samsung Biologics
MedCity News
Vir Biotechnology
COVID-19
Samsung BioLogics
drug manufacturing
Flag link:
GlaxoSmithKline and Vir Biotechnology Jump in Race to Treat and Prevent COVID-19
GlaxoSmithKline and Vir Biotechnology Jump in Race to Treat and Prevent COVID-19
Motley Fool
GSK
Vir Biotechnology
vaccines
COVID-19
Flag link:
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19
Pharmaceutical Business Review
Vir Biotechnology
Alnylam
COVID-19
RNAi
drug development
Flag link:
Scangos' Vir Biotechnology to test COVID-19 antibody 'in the summer'
Scangos' Vir Biotechnology to test COVID-19 antibody 'in the summer'
Fierce Biotech
Vir Biotechnology
COVID-19
George Scangos
Flag link:
Biogen signs on to manufacture clinical supplies for Vir's COVID-19 antibodies
Biogen signs on to manufacture clinical supplies for Vir's COVID-19 antibodies
Fierce Pharma
Biogen
Vir Biotechnology
George Scangos
COVID-19
drug manufacturing
Flag link:
These 4 Biotechs Have Selling Pressure on the Horizon
These 4 Biotechs Have Selling Pressure on the Horizon
Motley Fool
IPOs
Frequency Therpeutics
Viela Bio
Aprea Therapeutics
Vir Biotechnology
Flag link:
Alnylam, Vir team up to develop siRNAs to tackle COVID-19
Alnylam, Vir team up to develop siRNAs to tackle COVID-19
Fierce Biotech
Alnylam
Vir Biotechnology
RNAi
coronaviruses
COVID-19
siRNA
Flag link:
Vir Bio Identifies 2 Antibodies That Might Stop Coronavirus
Vir Bio Identifies 2 Antibodies That Might Stop Coronavirus
Motley Fool
Vir Biotechnology
monoclonal antibodies
COVID-19
Flag link:
Here's Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today
Here's Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today
Motley Fool
Inovio
Vir Biotechnology
Gilead Sciences
Wuhan Coronavirus
China
remdesivir
Flag link:
Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and More
Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and More
Xconomy
Vir Biotechnology
IPOs
infectious diseases
Flag link:
Vir Bio Plans IPO to Fund Clinical Trials of Infectious Disease Drugs
Vir Bio Plans IPO to Fund Clinical Trials of Infectious Disease Drugs
Xconomy
Vir Biotechnology
IPOs
infectious diseases
Flag link:
With $500M-plus, a buyout and two new billion-dollar pacts, upstart Vir is ready to roll on infectious diseases
With $500M-plus, a buyout and two new billion-dollar pacts, upstart Vir is ready to roll on infectious diseases
Endpoints
Vir Biotechnology
George Scangos
Alnylam
Visterra
Flag link:
Ex-Biogen chief George Scangos to spearhead a Gates-backed startup with big plans to fight infectious diseases
Ex-Biogen chief George Scangos to spearhead a Gates-backed startup with big plans to fight infectious diseases
Endpoints
Biogen
George Scangos
Bill Gates
Vir Biotechnology
Flag link: